Table 1.
Baseline Characteristics With and Without HPR According to Each Platelet Function Test.
| Baseline Patient Characteristics | All | VN | PFA | LTA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 30) | HPR (n = 15) | No HPR (n = 14) | P | HPR (n = 14) | No HPR (n = 14) | P | HPR (n = 10) | No HPR (n = 19) | P | |
| Age (years) | 57.4 (12) | 56 (12.5) | 57.9 (11.5) | .67 | 56.5 (14.1) | 59.7 (10) | .5 | 61.2 (14.2) | 55.2 (10.8) | .26 |
| Sex (male) | 26 (86.7%) | 12 (80%) | 13 (92.9%) | .32 | 13 (92.9) | 12 (85.7) | .5 | 9 (90) | 16 (84.2) | .67 |
| Systemic hypertension | 10 (33.3%) | 6 (40%) | 4 (28.6%) | .52 | 6 (42.9) | 4 (28.6) | .4 | 5 (50) | 5 (26.3) | .20 |
| Hyperlipidemia | 13 (43.3%) | 7 (46.7%) | 6 (42.9%) | .84 | 5 (35.7) | 7 (50) | .4 | 3 (30) | 9 (47.4) | .37 |
| Diabetes mellitus | 3 (10%) | 2 (13.3%) | 0 | .16 | 3 (21.4) | 0 | .07 | 1 (10) | 2 (10.5) | .96 |
| Active smoker | 19 (63.3%) | 11 (73.3%) | 8 (57.1%) | .36 | 10 (71.4) | 7 (50) | .25 | 6 (60) | 13 (68.4) | .65 |
| Body mass index, kg/m2 | 25.5 (4.7) | 25.5 (5.8) | 25.5 (3.5) | .98 | 26.4 (5.6) | 24.9 (3.8) | .42 | 26.7 (6.4) | 24.8 (3.6) | .4 |
| Past history of | ||||||||||
| Myocardial infarction | 2 (6.7%) | 0 | 2 (14.3%) | .13 | 0 | 2 (14.3) | .14 | 1 (10) | 1 (5.3) | .63 |
| PCI | 2 (6.7%) | 0 | 2 (14.3%) | .13 | 0 | 2 (14.3) | .14 | 1 (10) | 1 (5.3) | .63 |
| Treatment prior to index event | ||||||||||
| Aspirin | 1 (3.3%) | 0 | 1 (7.1%) | .29 | 0 | 1 (7.1) | .3 | 1 (10) | 0 | .16 |
| Clopidogrel | 2 (6.7%) | 0 | 2 (14.3%) | .13 | 0 | 2 (14.3) | .14 | 1 (10) | 1 (5.3) | .63 |
| Proton-pump inhibitor | 5 (16.7%) | 2 (13.3%) | 3 (21.4%) | .56 | 2 (14.3) | 3 (21.4) | .6 | 3 (30) | 2 (10.5) | .19 |
| Statins | 6 (20%) | 4 (26.7%) | 2 (14.3%) | .41 | 3 (21.4) | 2 (14.3) | .6 | 2 (20) | 4 (21.1) | .95 |
| Anterior wall STEMI | 5 (16.7%) | 3 (20%) | 2 (14.3%) | .68 | 2 (14.3) | 2 (14.3) | 1 | 2 (20) | 3 (15.8) | .77 |
| Inferior wall STEMI | 23 (76.7%) | 12 (80%) | 10 (71.4%) | .59 | 12 (85.7) | 10 (71.4) | .36 | 8 (80) | 14 (73.7) | .70 |
| Other infarct location | 3 (10%) | 1 (6.7%) | 2 (14.3%) | .5 | 1 (7.1) | 2 (14.3) | .54 | 1 (10) | 2 (10.5) | .96 |
| Left ventricular ejection fraction, % | 52.5 (8.7) | 51.7 (8.4) | 53.4 (9.5) | .61 | 51.8 (9.3) | 53.4 (8.6) | .6 | 51.5 (8.8) | 53.1 (8.9) | .65 |
| Systolic blood pressure, mm Hg | 146 (29) | 142.9 (31.4) | 147.9 (27.8) | .65 | 144.1 (31.8) | 149.6 (29) | .6 | 157.2 (23.5) | 139.8 (31.2) | .1 |
| Heart rate, beats/min | 78 (18) | 79 (21) | 77 (16) | .76 | 78 (22) | 77 (15) | .9 | 84 (22) | 76 (16) | .35 |
| Killip class ≥II | 2 (6.7%) | 1 (6.7%) | 1 (7.1%) | .96 | 1 (7.1) | 1 (7.1) | 1 | 1 (10) | 1 (5.3) | .63 |
| GRACE score | 129.6 (26.6) | 128.9 (27.6) | 129.4 (27.3) | .96 | 129.4 (28.8) | 130.1 (27.3) | .95 | 133.4 (30.5) | 127.3 (25.7) | .59 |
| CRUSADE score | 27.7 (12.5) | 26.3 (14.2) | 27.9 (10) | .73 | 30.1 (12.9) | 27 (12.2) | .5 | 30.6 (12.7) | 26.8 (12.5) | .45 |
| Time points, min | ||||||||||
| Pain to FMC | 112.5 (81) | 107.2 (60.2) | 109.6 (97.9) | .94 | 113 (71.5) | 107 (96.3) | .8 | 110.7 (73.8) | 116.8 (87.1) | .84 |
| Pain to FL | 156.1 (86.4) | 151 (65.3) | 154.1 (105.8) | .92 | 152.1 (75.8) | 156.4 (103.4) | .9 | 153.5 (73.9) | 159.4 (96) | .85 |
| FL to PCI | 1057.6 (563.4) | 1078 (648.8) | 1002.4 (484) | .72 | 1157.5 (659.9) | 1041.9 (443) | .6 | 1217.1 (703.4) | 941.4 (463.4) | .28 |
| FMC to PCI | 1101.1 (567) | 1121.6 (652.6) | 1046.9 (489) | .73 | 1196.3 (662.5) | 1091.1 (450.2) | .6 | 1259.6 (700.9) | 983.9 (470) | .28 |
| Admission biological characteristics | ||||||||||
| Hemoglobin, g/dL | 14.5 (1.2) | 13.9 (1) | 15.1 (1.1) | .006 | 14.2 (1.1) | 14.8 (1.2) | .20 | 14.2 (1.1) | 14.6 (1.3) | .46 |
| Hematocrit, % | 40.1 (10.2) | 41.3 (2.5) | 38.4 (14.7) | .49 | 42.2 (2.6) | 37.8 (14.6) | .28 | 42.7 (3.2) | 38.4 (12.4) | .17 |
| White blood cell count, G/L | 12.2 (4.5) | 12.6 (4.3) | 12 (5) | .74 | 13.8 (6.1) | 10.7 (1.8) | .08 | 12.5 (5.1) | 12.2 (4.5) | .88 |
| Platelet count, G/L | 252.4 (72.7) | 262.7 (80.8) | 243.6 (66.9) | .49 | 269.4 (73.4) | 225 (44.2) | .07 | 250.9 (72.3) | 254.9 (76.4) | .89 |
| Kaliemia, mmol/L | 4.3 (0.4) | 4.2 (0.4) | 4.3 (0.4) | .63 | 4.3 (0.4) | 4.3 (0.4) | .7 | 4.2 (0.5) | 4.3 (0.3) | .67 |
| Creatinine clearance, mL/min | 91.2 (32.2) | 99.3 (40.2) | 85 (19.2) | .23 | 93.4 (41.8) | 86.6 (21.9) | .6 | 86.4 (39.2) | 93.7 (29.6) | .61 |
| Prothrombin rate, % | 95.4 (6.9) | 96 (7.7) | 95.3 (6.4) | .8 | 95.4 (7.9) | 95.5 (6.6) | .9 | 95.8 (4.7) | 96.2 (6.9) | .86 |
| aPTT, seconds | 1.2 (0.3) | 1.2 (0.3) | 1.2 (0.3) | .77 | 1.2 (0.3) | 1.2 (0.3) | .9 | 1.1 (0.3) | 1.2 (0.3) | .76 |
| Anti-Xa, IU | 0.5 (0.2) | 0.5 (0.2) | 0.6 (0.2) | .42 | 0.55 (0.2) | 0.49 (0.3) | .5 | 0.5 (0.2) | 0.55 (0.2) | .66 |
| Adjunctive therapy to FL | ||||||||||
| Clopidogrel loading dose 300 mg | 28 (93.3%) | 14 (93.3%) | 13 (92.9%) | .96 | 13 (92.9) | 13 (92.9) | 1 | 9 (90) | 18 (94.7) | .63 |
| Enoxaparin | 27 (90%) | 12 (80%) | 14 (100%) | .08 | 12 (85.7) | 13 (92.9) | .5 | 8 (80) | 18 (94.7) | .21 |
| Unfractionated heparin | 3 (10%) | 3 (20%) | 0 | .08 | 2 (14.3) | 1 (7.1) | .5 | 2 (20) | 1 (5.3) | .21 |
Abbreviations: aPTT, activated partial thromboplastin time; CRUSADE, Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines; FL, fibrinolysis; FMC, first medical contact; GRACE, Global Registry of Acute Coronary Events; HPR, high platelet reactivity; LTA, light transmittance aggregometry; PFA, INNOVANCE PFA P2Y; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TL, thrombolysis; VN, VerifyNow.